Incidence and etiology of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most frequent and malignant diseases worldwide. With an estimated 560 000 newly diagnosed cases per year, it is the third most common cause of cancer deaths (Pisani et al., 1999; Parkin et al., 2005) . Although this malignancy is less common, but increasing in Westerndeveloped countries such as the USA, with an incidence of 2.8-6.1 (Caucasian vs African-American) per 100 000 (El-Serag and Mason, 1999) , it is endemic in China, Taiwan, Korea and sub-Saharan Africa, where the incidence is between 20 and 100 cases per 100 000 inhab itants ( Figure 1a and b) (Sherman, 1995; DominguezMalagon and Gaytan-Graham, 2001 ). Furthermore, HCC is a leading cause of cancer-related death in these countries, because less than 3% of these patients survive more than 5 years (Di Bisceglie et al., 1988) .
The major HCC risk factors include various viruses and chemicals, and are summarized in Figure 2 . Among those, chronic hepatitis B (HBV) and C (HCV) viruses infections attribute to HCC development in more than 80% of the HCC cases worldwide . Other known risk factors of HCC, including dietary aflatoxin B 1 (AFB 1 ) intake, cigarette smoking or heavy alcohol consumption, can have synergistic effects (reviewed by Ross et al., 1992; Qian et al., 1994; Kew, 2003; Yu and Yuan, 2004) . Besides these risk factors, there are several genetic disorders (Figure 2 ) such as hemochromatosis (an iron overload disease) that are associated with an increased risk of HCC Kowdley, 2004) . Regardless of its etiology, cirrhosis alone is also an independent risk factor for HCC.
In recent years, we have gained a better understanding of the genetic, environmental interactions and mechanisms associated with the development of HCC. For example, genomic and gene expression analyses have identified key dysregulated signal transduction pathways involved in liver carcinogenesis (Thorgeirsson and Grisham, 2002; Ye et al., 2003; Budhu et al., 2006; Lee and Thorgeirsson, 2006) . These studies and others have generated a new paradigm of metastasis ( Figure 3 ) that is not mutually exclusive to the hypothesis of multistage carcinogenesis depicted in Figure 2 . This review will focus on the various functions and involvement of the p53 tumor suppressor gene (TP53) in liver carcinogenesis.
TP53 mutation archeology in HCC
The p53 response pathway is frequently defective in human cancers including HCC. The frequency of TP53 mutations and the mutation spectra vary in different geographic areas (Figure 1a-c) , and presumably reflect differences in both etiological agents and host susceptibility factors (Hussain and Harris, 1998; Olivier et al., 2004) .
Causation evaluated by the Bradford-Hill criteria
The presence of specific TP53 mutational hotspots in different types of human cancer implicates environmental carcinogens and endogenous processes in the etiology of human cancer. The presence of a characteristic TP53 mutation is a putative molecular link between the exposure to a particular carcinogen and a specific type of cancer, for example, AFB 1 exposure and codon 249 ser mutations in HCC (Figure 1b and c) . In addition, the detection of such a particular mutation in normal-appearing tissue provides further support for the involvement of a specific carcinogen in a specific human cancer. Once a careful assessment of causation has been carried out for a presumed carcinogen association, its associated molecular damage, and the final disease, individuals with an increased cancer risk may be identified. For this approach, appropriate criteria as proposed by Bradford-Hill, might be used for the assessment (Hill, 1965) . Using the 'weight of the evidence' principle, these criteria include strength of association (consistency, specificity and temporality) and biological plausibility. One prime example for the use of the BradfordHill criteria is the association of AFB 1 dietary intake followed by TP53 249 ser mutations and liver carcinogenesis (Table 1) (Hussain and Harris, 1998; Staib et al., 2003) . However, geographic location, race and gender may also influence an individual's susceptibility for cancer risk.
Aflatoxin B 1
TP53 mutations indicate that the sites and features of DNA base changes differ among the various human tumor types. In human HCC, the mutational spectrum has provided a strong molecular link between carcinogen exposure and cancer. In geographical areas of AFB 1 dietary exposure (a mycotoxin contaminating foods like corn, rice and peanuts) and chronic viral hepatitis, like China and Africa, a point mutation at the third position of codon 249 ser resulting in a G:C to T:A transversion was common in HCC (Figure 1a-c) (Bressac et al., 1991; Hsu et al., 1991) . These results have been confirmed and extended by others (Scorsone et al., 1992; Li et al., 1993; Lunn et al., 1997) . This codon 249 mutation can also be detected in serum DNA from patients from the Gambia with HCC, so that TP53 mutant DNA may be a biomarker of exposure to AFB 1 and possibly early HCC (Kirk et al., 2000) . Their most recent results indicate a multiplicative effect on HCC risk between the AFB 1 -induced TP53 249 ser mutation, as monitored by the detection of plasma TP53 249 ser , and chronic viral hepatitis (Kirk et al., 2005) (Table 2) . These results are consistent with the TP53 mutation load of 249 ser mutant cells in nontumorous liver that has a dose-dependent relationship with the intake of AFB 1 . In geographic regions, such as Qidong and China, 40% of HCC can be attributable to dietary AFB 1 exposure (Ming et al., 2002) . Several studies support the findings of a positive association between the 249 ser mutation of TP53 and AFB 1 exposure, whereas the analysis of HCCs in areas of low AFB 1 intake always reported a different mutational spectrum (Ozturk, 1991; Kress et al., 1992; Oda et al., 1992) . In vitro studies exposing human liver cell lines to AFB 1 presented the same 249 ser mutational pattern of TP53 (Aguilar et al., 1993; Mace et al., 1997) , as it has been reported in the epidemiological studies ( Figure 1c) . There are at least two possible explanations for these findings. Aguilar et al. (1994) have shown a higher relative abundance of the 249 ser mutant liver cells, in nontumorous liver, by using a highly sensitive genotypic mutation assay. They suggested that this early mutational event may be due to the high mutability of the third base at codon 249 to AFB 1 , as suggested by previous in vitro studies in human liver cells (Aguilar et al., 1993; Cerutti et al., 1994) . Another possible explanation might be that the 249 ser mutant p53 protein may provide a special growth and/or survival advantage to these liver cells (Puisieux et al., 1995) . The latter hypothesis is supported by the following findings: first, the transfection of a TP53 249 ser mutant into p53-negative human liver cancer cells resulted in enhanced cell growth that is consistent with a gain of function of p53 249 ser (Ponchel et al., 1994) ; second, the introduction of a murine TP53 mutation, corresponding to human codon 249 into a murine hepatocyte cell line, resulted in a selective growth advantage (Dumenco et al., 1995) ; third, the 249 ser mutant inhibits wild-type p53-mediated apoptosis, resulting in increased cell survival and fourth, the 249 ser mutant is more effective than other mutants in inhibiting wild-type p53 transactivation activity in human liver cells .
In addition to the direct mutagenicity of the metabolically activated AFB 1 to the 8, 9-epoxide that binds to DNA and forms the promutagenic N7dG adduct (Buss et al., 1990; Guengerich et al., 1996) , AFB 1 can cause oxidative and nitrosative stress, and may indirectly induce TP53 249 ser mutations by lipid peroxidation ( Figure 4 ). Our recent studies indicate that oxidative-stress-generated 4-hydroxynonenal can induce TP53 249 ser mutations in vitro . However, although chronic inflammation associated with HBV or HCV infection can also cause lipid peroxidation, TP53 249 ser mutations are uncommon without AFB 1 exposure. These observations argue against this indirect mechanism as a major pathway to TP53 249 ser mutation in HCC. HCC occurring in individuals with oxyradical overload diseases, such as hemochromatosis, contain TP53 mutations occurring primarily at A:T base pairs and TP53 249 ser mutations have not been observed (Marrogi et al., 2001) . The combination of HBV and AFB 1 exposure may be critical to the high frequency of TP53 249 ser mutations in HCC (Ming et al., 2002) . We are not aware of HCC studies occurring in a population, if it exists, exposed only to AFB 1 without HBV infection. AFB 1 induces HCC in nonhuman primates and with neonatal exposure in mice, but TP53 mutations are rare (Fujimoto et al., 1992; Tong et al., 2006) . Nevertheless, attenuated p53 function cooperates with telomere-induced chromosomal instability in a murine model of HCC carcinogenesis .
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HBV and HCV as oncoviruses in liver carcinogenesis
The hepatitis viruses, HBV and HCV, induce liver injury, hepatocyte death and promote hepatocarcinogenesis. It is still not clear whether the virus infection is causing the tumor initiation or the subsequent inflammation, leading to liver regeneration and cirrhosis, which act as a tumor promoter in hepatocarcinogenesis. Available data suggest that viral proteins undergo various interactions with host proteins leading to an alteration of the cellular gene expression, which may contribute to a virus-associated carcinogenesis. HBV is a hepadna virus with a partially doublestranded DNA molecule, which is about 3.2 kb long and consists of four open reading frames encoding the envelope protein, the nucleocapsid (core) protein, the viral reverse transcriptase, and the X gene of HBV (HBx) protein.
HBx is required for the transcription of the viral genome.
Among these, the HBx protein has been the focus of attention, because it seems to play a strong causal role in HCC (Tang et al., 2006) . The most commonly integrated HBV gene is the HBx gene ( Figure 5 ) (Unsal et al., 1994) .
HBx decreases p53 binding to XPB (Wang et al., 1994) , which is both involved in nucleotide excision repair and in transcription as a basic transcription factor (Schaeffer et al., 1993) , and interacts with various other DNA repair-associated proteins or enzymes, including DNA helicases (Qadri et al., 1996; Jia et al., 1997) . HBx itself has been shown to attenuate nucleotide excision repair and alter the AFB 1 -induced mutation spectrum (Becker et al., 1998; Groisman et al., 1999; Jia et al., 1999; Mathonnet et al., 2004) . HBx transgenic mice have increased G:C to T:A transversions induced by AFB 1 when compared with AFB 1 -exposed wild-type mice (Madden et al., 2002) . These interferences of HBx with the cellular DNA repair system provide another mechanism of how HBV contributes to liver carcinogenesis. Figure 1 (a) Worldwide incidences of HCC with pie diagrams of TP53 mutation patterns for various countries and continents according to the IARC TP53 mutation database (http://www.iarc.fe/p53/index.html). A high frequency of G:C to T:A mutations is found in high incidence areas of both endemic HBV infection and dietary AFB 1 exposure. (b) TP53 mutational spectra in HCC from different geographic areas of Asia. TP53 249 ser mutations are found only in high incidence geographic areas with endemic HBV infections and dietary AFB 1 exposure. (c) Schematic representation of the p53 molecule. The human p53 protein consists of 393 amino acids with functional domains, evolutionarily conserved domains and regions designated as mutational hotspots. Functional domains include the transactivation region (gold block), sequence-specific DNA-binding region (amino acids 100-293), nuclear localization sequence (amino acids 316-325, dark green block) and oligomerization region (amino acids 319-360, light green block). Evolutionarily conserved domains (amino acids 17-29, 97-292 and 324-352; rose areas) were determined using the Multiple Alignment Construction and Analysis Workbench (MACAW) program. Seven mutational hotspots and evolutionarily conserved regions within the large conserved domain are also identified (amino acids 130-142, 151-164, 171-181, 193-200, 213-233, 234-258 and 270-286 , blue blocks). Vertical lines above the schematic represent missense mutations. The majority of these mutations are in the conserved hydrophobic midregion of the protein, which is required for the sequence-specific binding to DNA. The nonmissense mutations (nonsense, frameshift, splicing and silent) are distributed throughout the protein and determined primarily by sequence context, whereas deletions and insertions are more common in the N-and C-terminus of the TP53 gene. The pie charts on the left show the mutational spectra of codons 157 and 249, and the frequency evoked by AFB 1 intake. In contrast, the pie chart on the right includes all TP53 mutations in HCC.
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We and others have shown that HBx binds to p53 and inactivates p53-dependent activities (Feitelson et al., 1993; Wang et al., 1994 Wang et al., , 1995 Ueda et al., 1995; Elmore et al., 1997) , including p53 sequence-specific DNAbinding activity in vitro (Wang et al., 1994) , p53-mediated transcriptional activation in vivo (Wang et al., 1994) and represses the TP53 transcription (Lee and Rho, 2000) . Moreover, HBx deregulates cell cycle check point controls and blocks p53-mediated apoptosis (Lucito and Schneider, 1992; Feitelson et al., 1993; Bennett et al., 1995; Wang et al., 1995; Miura et al., 1997; Chan and Ng, 2006) . Interestingly, tumorderived HBx mutants that lacked their transcriptional cotransactivation activity as well as proapoptotic activity (Sirma et al., 1999) , still retained their p53-binding functions and blocked p53-mediated apoptosis (Huo et al., 2001 . (Figure 6 ) Furthermore, by losing the proapoptotic ability, the mutant HBx enhanced the transforming ability of ras and myc (Tu et al., 2001) . The abrogation of p53-mediated apoptosis by HBx (also reviewed by Arbuthnot et al., 2000; Bergsland, 2001; Murakami, 2001) (Kuang et al., 2004 (Kuang et al., , 2005 . The double mutant resides in the HBx open reading frame within HBV, and results in lysine to methionine and valine to isoleucine at HBx codons 130 and 131, respectively. The functional significance of this HBx double mutant is not known.
To gain a better insight into HCV-related hepatocarcinogenesis, microarray technology has been applied in several studies. Analysis of HCV-associated cirrhosis revealed an upregulation of proinflammatory, proapoptotic and pro-proliferative genes, which might reflect groups of genes being involved in HCV-related cirrhosis progressing to HCC (Honda et al., 2001; Shackel et al., 2002) . Gene expression profiles of the HCV genotypes Figure 3 Clonal and dual proclivity models of tumor evolution to metastasis. In the clonal evolution model, a normal hepatocyte (green) progresses to a tumor through clonal expansion of an initiated cell with a mutation (yellow), followed by the acquisition of sequential mutations (red) that support metastasis. In the dual proclivity model, multiple tumor-initiating events are concurrent in premalignant lesions before tumor formation and metastasis. These events are inherent in the primary tumor and/or are modulated by the stromal environment. (Budhu et al., 2005) . 
Chronic inflammation and cancer
Chronic inflammation and infection is frequently associated with increased cancer risk, although exceptions can be cited, including rheumatoid arthritis and human papillomavirus infection (Table 3; Hussain et al., 2003) . Infection with HBV and HCV viruses cause inflammation with the release of free radicals, chemokines and cytokines resulting in DNA damage, cell proliferation, fibrosis and angiogenesis. The p53 pathway is a key responder to inflammatory stress (Staib et al., 2005) . Free radicals, for example, reactive nitrogen or oxygen species, can directly damage DNA and proteins, and indirectly damage these macromolecules via lipid peroxidation (Figure 4) . The p53 pathway responds to lower levels of DNA damage by cell cycle checkpoint arrest, facilitating DNA repair as an adapter 
Figure 6
The HBV-X gene product and its mutations. Both missense mutations and deletions are frequent in tumor-derived HBV-X. The nuclear export signal (NES) and retention of p53 binding is found in the integrated HBV-X gene in human cancers.
TP53 mutations and HCC SP Hussain et al in the formation of DNA repair protein complexes and transcriptional transactivation of DNA repair genes (Sengupta and Harris, 2005) , and to extensive DNA damage by mediating cell death, p53 also contributes to these processes by switching from increased expression of anti-to pro-oxidant genes. p53 can both transcriptionally transrepress pro-oxidant/nitrosative genes, for example, nitric oxide synthases (NOS)2, and transactivate antioxidant genes expressing glutathione peroxidase, aldehyde dehydrogenase, and Mn-superoxide dismutase, sestrins, and TIGAR (TP53-induced glycolysis and apoptosis regulator) (Table 4 ). An animal model of the Li-Fraumeni syndrome has provided new insights into the protective antioxidative and ntirosative function of p53. TP53 null mice are predisposed to lymphoma and leukemia (Donehower et al., 1992) . If these mice are fed anti-oxidative and -nitrosative agent, that is, N-acetylcysteine, the number of tumors was markedly decreased in support of the protective function of p53 in tumor suppression (Sablina et al., 2005) . Growing evidence indicates that nitric oxide (NO ), an important bioregulatory and signalling molecule, may play a significant role in carcinogenesis (Moncada et al., 1991; Bredt and Snyder, 1994; Nathan and Xie, 1994; Hentze and Kuhn, 1996; Tamir and Tannenbaum, 1996; Ambs et al., 1997) . NO is catalysed by a family of enzymes known as NOS (Marletta, 1993; Forstermann and Kleinert, 1995) . The isoforms NOS1 and NOS3 are found to be constitutively expressed, for example, in neurons (NOS1) or endothelial cells (NOS3). They produce NO levels ranging from pico-to nanomolar concentrations. In contrast, NOS2 (also called iNOS) requires induction generally, but is able to produce NO concentrations in the micromolar range (reviewed by Ambs et al., 1997) . NOS2 gene expression can be induced by bacterial endotoxins, proinflammatory cytokines or hypoxia (Wild et al., 1986; Nussler et al., 1992; Lombard and Guarente, 2000) in many cell types, including macrophages (Xie et al., 1992) and hepatocytes (Mowat et al., 1990; Lombard and Guarente, 2000; Vodovotz et al., 2004) as well as in a variety of human tumors (reviewed by Ambs et al., 1997) . During chronic viral hepatitis, the upregulation of certain proinflammatory cytokines, like tumor necrosis factor-a (TNF-a) and interferon-g (IFN-g), has been repeatedly demonstrated (Gonzalez-Amaro et al., 1994; Mihm et al., 1996) . These proinflammatory cytokines, TNF-a, IFN-g and IL-1, induce NOS2 gene expression, which leads to increased NO concentrations in human hepatocytes (de Vera et al., 1996; Laskin et al., 1998) . In addition, NOS2 is also induced directly by the HBV and HCV. In vitro studies from Elmore et al. (1997) ; Amaro et al. (1999) ; Majano et al. (1998) demonstrate that the HBx protein is capable of transcriptional transactivation of NOS2. An induction of the NOS2 expression has also been seen after hepatocytes are exposed to woodchuck hepatitis virus surface antigen (Liu et al., 1994) . In patients with HBV or HCV infection, a consistent upregulation of hepatic NOS2 has been shown (Kane et al., 1997; Vodovotz et al., 2004) .
We and others were able to show that this NO -related DNA damage leads to p53 accumulation and p53-mediated apoptosis (Forrester et al., 1996; Messmer and Brune, 1996) (Figure 7) . Moreover, we presented (Forrester et al., 1996) ALDH4 (Yoon et al., 2004) MnSOD Mouse model (Ambs et al., 1998b) SESN 1 and 2 (Sablina et al., 2005) TIGAR (Bensaad et al., 2006) TP53 mutations and HCC SP Hussain et al results indicating that p53 is a transcriptional transrepressor of NOS2 expression in vivo and attenuates an excessive NO production in a regulatory negative feedback loop (Forrester et al., 1996; Ambs et al., 1998b; Hussain et al., 2001) . NO can also activate the arachidonic acid pathway by enhancing the enzymatic activity of cyclooxygenase 2 (COX2) (Figure 7 ). The mechanism of this activation is by NOS2 binding and nitrosylation of COX2 (Kim et al., 2005) . Increased COX2 activity results in the release of prostaglandin 2E (PGE2), that diminishes the apoptotic pathway and activates the WNT pathway (Castellone et al., 2005; Buchanan and DuBois, 2006) . The WNT signal transduction and COX2 pathways are key contributors to liver carcinogenesis (Thorgeirsson and Grisham, 2002) , and also predict poor survival of patients with HCC (Kondo et al., 1999) . The WNT pathway can also transcriptionally activate both NOS2 and COX2 by T-cell factor (TCF)4-b-catenin binding to positive response elements in their promoters (Araki et al., 2003; Du et al., 2006) . Therefore, the NOS2 and COX2 are concomitantly activated by pro-inflammatory cytokines, hypoxia and the WNT pathway. The WNT pathway is frequently activated in HCC associated with high AFB 1 exposure (Devereux et al., 2001 ). COX2 activity is amplified by nitrosylation following its physical interaction with NOS2. NO can both damage DNA to induce the anticarcinogenic p53 stress response pathway and mutate cancer-related genes including TP53. PGE2 attenuates apoptosis (Gupta and DuBois, 2001) , which may allow survival of hepatocytes with DNA damage and increase the probability of somatic mutations. As NO -induced apoptosis can be p53 dependent, cells with mutant TP53 have a clonal expansion advantage. Consistent with this model, we have found a significant association as well as a doseresponse relationship between TP53 mutations (G:C to A:T transition at cytosine guanine dinucleotide (CpG) sites) and an increased NOS2 activity in patients with colon cancer (Ambs et al., 1999) . Furthermore, we and others have demonstrated a positive association of NOS2 expression and a comparable TP53 mutational spectrum in lung cancer (Fujimoto et al., 1998; Ambs et al., 1998a) . This TP53 mutation spectrum is consistent with increased rates of N 2 O 3 -induced deamination of 5-methylation at CpG sites. In summary, oxidative/ nitrosative stress, mediated by free radicals, which is also induced by the cytokine profile of various inflammatory hepatic disorders like HBV and HCV infection, or hemochromatosis, can act as an endogenous carcinogen to increase TP53 mutations and provide a microenvironment allowing a clonal growth advantage for cells with TP53 mutations. Figure 7 Model of the interactive pathways in nitrosative-stressinduced TP53 mutation. NOS2 and COX2 are positively regulated by hypoxia, proinflammatory cytokines, and the WNT signal transduction pathway. NOS2 produces a high concentration of NO that can both damage DNA to induce mutations in cancer-related genes, for example, TP53, and induce p53-dependent cell cycle arrest and apoptosis, so that cells containing mutated TP53 attain selective clonal growth and survival advantages. NOS2 can physically bind COX2 and activate it by nitrosylation. COX2 can increase lipidperoxidation to produce unsaturated aldehydes that can induce TP53 mutations, and increase PGE2 concentrations. PGE2 can attenuate p53-mediated apoptosis and activate the WNT pathway, resulting in increased b-catenin that with TCF-4, transcriptionally activates NOS2 and COX2. High amounts of p53 can participate in negative feedback loops in the regulation of NOS2 and COX2. Lesser amounts of p53 can enhance COX2 accumulation.
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